Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hearing Disorders: HELP
Articles by Sameh E. Soliman
Based on 1 article published since 2010
(Why 1 article?)
||||

Between 2010 and 2020, Sameh E. Soliman wrote the following article about Hearing Disorders.
 
+ Citations + Abstracts
1 Clinical Trial Clinical and genetic associations for carboplatin-related ototoxicity in children treated for retinoblastoma: A retrospective noncomparative single-institute experience. 2018

Soliman, Sameh E / D'Silva, Crystal N / Dimaras, Helen / Dzneladze, Irakli / Chan, Helen / Gallie, Brenda L. ·Faculty of Medicine, Department of Ophthalmology, University of Alexandria, Alexandria, Egypt. · Department of Ophthalmology and Vision Science, Hospital for Sick Children, Toronto, Canada. · Department of Medical Biophysics, University of Toronto, Toronto, Canada. · Department of Ophthalmology and Vision Science, University of Toronto, Toronto, Canada. · Child Health Evaluative Sciences Program, SickKids Research Institute, Toronto, Canada. · Division of Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada. · Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Canada. ·Pediatr Blood Cancer · Pubmed #29350448.

ABSTRACT: BACKGROUND: Children with retinoblastoma treated with carboplatin chemotherapy risk moderate to severe, irreversible hearing loss. Based on published evidence, we hypothesized that ototoxicity risk is associated with clinical parameters and variants in candidate genes in drug metabolism pathways (methyltransferases [thiopurine S-methyltransferase, TPMT] and [catechol-O-methyltransferase, COMT], and drug transporter ABCC3). PROCEDURE: We retrospectively reviewed clinical records of patients with retinoblastoma treated with carboplatin chemotherapy regarding age (at diagnosis and chemotherapy initiation), chemotherapy sessions (cycles number, drug doses, and cumulative carboplatin dose), and hearing loss (defined as ototoxicity ≥grade 2 by at least one classification system). Blood samples were genotyped for genetic variants in TPMT (rs12201199, rs1800460), COMT (rs4646316, rs9332377), and ABCC3 (rs1051640) by quantitative PCR and confirmed by allele-specific PCR. Univariate statistical tests, receiver-operating characteristic analysis, and Kaplan-Meier curves were used to examine the association between hearing loss, clinical factors, and variants in candidate genes. RESULTS: Audiometric data and stored DNA were available for 71 patients with retinoblastoma (88% carried an RB1 pathogenic variant allele). Median carboplatin cumulative dose was 1,400 mg/m CONCLUSIONS: We observed a 25% prevalence of ototoxicity in patients with retinoblastoma treated with carboplatin, higher than previously published. Age at chemotherapy initiation was associated with carboplatin-induced ototoxicity, with children <4.25 months of age at highest risk.